Could Cancer Vaccines Change How Certain Cancers Are Prevented or Treated?
Vaccines are usually associated with preventing infections, but researchers are also using vaccination strategies to prevent or treat certain cancers. Some cancer vaccines already help prevent cancers caused by viruses, while therapeutic cancer vaccines are designed to train the immune system to recognize and attack cancer cells in someone who already has cancer. One therapeutic vaccine is already approved for certain advanced prostate cancers, but many newer approaches—including personalized vaccines built around the unique mutations in a person's tumor—remain experimental. Early clinical studies involving cancers such as pancreatic and kidney cancer have produced encouraging immune responses and recurrence findings, although larger trials are needed before these approaches can become routine treatment. Researchers are also investigating whether vaccines might someday prevent some non-viral cancers in people at particularly high risk. Understanding the difference between what cancer vaccines can do today and what researchers hope they might do in the future is essential as this rapidly developing field moves forward.
What Exactly Is a Cancer Vaccine?
Cancer vaccines fall into two fundamentally different categories: vaccines that help prevent certain cancers and vaccines designed to treat cancer that has already developed. Prevention vaccines generally work by stopping infections known to cause cancer, whereas treatment vaccines aim to direct the immune system against cancer cells.
This distinction matters because the phrase “cancer vaccine” can otherwise create the misleading impression that one injection can prevent or cure cancer in general.
Cancer prevention vaccines and cancer treatment vaccines are not the same
Feature | Cancer prevention vaccines | Cancer treatment vaccines |
Main purpose | Reduce the risk of cancers caused by certain infections | Help the immune system recognize and attack cancer cells |
Given to | People before the targeted cancer develops | People who already have cancer |
Main target | Cancer-causing infectious agents, such as HPV or hepatitis B virus | Antigens or other targets associated with cancer cells |
Current examples | HPV and hepatitis B vaccination | Sipuleucel-T for certain advanced prostate cancers |
Personalized to a tumor? | No | Some experimental vaccines are |
Current status | Established prevention for specific virus-associated cancers | Limited approved use; many approaches remain experimental |
The National Cancer Institute overview of cancer treatment vaccines describes therapeutic cancer vaccines as a form of immunotherapy. Rather than preventing an infection, these vaccines attempt to strengthen immune responses against substances, called antigens, associated with cancer cells.
Which Cancers Can Vaccines Already Help Prevent?
Vaccination already prevents some cancers indirectly by preventing infections that can eventually cause them. The clearest examples are vaccination against human papillomavirus (HPV) and hepatitis B virus (HBV).
How does the HPV vaccine prevent cancer?
Persistent infection with certain types of HPV can cause several cancers. Vaccination helps prevent infection with the HPV types targeted by the vaccine before those infections can initiate the chain of biological changes that may eventually lead to cancer.
According to the NCI HPV vaccine fact sheet , HPV vaccination can prevent infections associated with cancers of the cervix, vagina, vulva, anus, penis, and oropharynx, which includes part of the throat.
Importantly, HPV vaccination is preventive rather than a treatment for an existing cancer. Researchers are separately studying therapeutic HPV vaccines intended to stimulate immune responses against HPV-infected abnormal cells, but those approaches should not be confused with established preventive HPV vaccination.
How does hepatitis B vaccination help prevent liver cancer?
Long-term hepatitis B infection can cause serious liver disease and increase the risk of liver cancer. Preventing HBV infection through vaccination therefore reduces an important underlying cause of liver cancer.
This demonstrates a major principle of cancer prevention: a vaccine does not necessarily need to target a cancer cell directly to prevent cancer. Preventing an infection that contributes to cancer development can interrupt the process much earlier.
Cancer vaccines are not only a future possibility. Vaccination against HPV and hepatitis B already helps prevent specific cancers by preventing cancer-causing viral infections. The more experimental frontier is developing vaccines that directly prevent or treat cancers not caused by viruses.
How Could Vaccines Be Used to Treat Cancer?
Therapeutic cancer vaccines attempt to teach the immune system to recognize features of cancer cells and attack them more effectively. They are a form of cancer immunotherapy and are given after cancer has developed rather than to healthy people as routine cancer prevention.
This is challenging because cancer develops from a person's own cells. Cancer cells can therefore share many features with normal cells, making it harder for the immune system to identify a target that is both specific enough and biologically important.
What are cancer antigens?
Cancer cells can contain or display molecules known as antigens that the immune system may be able to recognize. Some treatment vaccines attempt to expose the immune system to selected cancer-associated antigens so immune cells—particularly T cells—can recognize cells carrying those targets.
Cancer treatment vaccines can be developed in several ways. According to NCI, they may use a patient's tumor cells, particular tumor-associated antigens, or immune cells known as dendritic cells.
Is any cancer treatment vaccine already approved?
Yes. Sipuleucel-T is an approved cellular immunotherapy used for certain people with advanced prostate cancer that has spread and is no longer responding to hormone treatment. It is produced using a patient's own immune cells and is designed to stimulate an immune response against prostate cancer.
Its existence is important because it demonstrates that therapeutic cancer vaccination is biologically and clinically possible. However, it does not mean that treatment vaccines are currently available for most cancers.
What Are Personalized Cancer Vaccines?
Personalized cancer vaccines are designed around molecular features of an individual patient's tumor. Researchers analyze tumor material to identify mutations that can produce abnormal proteins, or parts of proteins, called neoantigens that may be recognizable by the immune system.
The resulting vaccine can then include selected neoantigen targets unique to that person's cancer.
Why are neoantigens interesting to researchers?
Neoantigens can arise from mutations in cancer cells and may not be present in normal cells. In principle, this gives the immune system a more cancer-specific target.
Researchers can sequence a tumor, identify potential neoantigens, predict which are most likely to stimulate an immune response, and manufacture an individualized vaccine containing selected targets.
Several technologies are being investigated for delivering this information to the immune system, including peptides, DNA, and messenger RNA (mRNA).
This personalized approach is scientifically attractive, but it is also complex. Tumor sampling, genetic analysis, target selection, vaccine manufacturing, treatment timing, cost, and determining which patients are most likely to benefit all present practical challenges.
What Does Research on mRNA and Neoantigen Cancer Vaccines Show?
Early human trials have produced encouraging results in several cancers, but personalized neoantigen vaccines remain experimental for these uses. Small studies can show whether a vaccine stimulates the intended immune response and provide early evidence of clinical benefit, but larger controlled trials are needed to establish safety and effectiveness.
A 2025 NCI report described small trials of personalized neoantigen vaccines after surgery in people with pancreatic and kidney cancers. Researchers created individualized vaccines by analyzing each person's tumor mutations and selecting neoantigens to target.
What happened in the pancreatic cancer study?
In the pancreatic cancer study described by NCI, 16 patients received a personalized mRNA-based vaccine as part of a treatment approach that also included an immune checkpoint inhibitor and chemotherapy. Eight patients developed the immune response researchers were looking for.
Among those eight responders, six remained cancer-free at approximately three years of follow-up, while two had experienced recurrence. Some vaccine-responsive T cells were still able to recognize their targeted antigens as long as four years after vaccination.
These findings are promising but should not be interpreted as proof that the vaccine prevented recurrence. The study was small, and additional treatment was given alongside the vaccine. NCI emphasizes that larger clinical trials are needed to establish safety and efficacy.
Are other cancers being studied?
Yes. Personalized neoantigen vaccine approaches are being investigated across multiple solid tumors. Current NCI-listed studies include experimental vaccines for cancers such as melanoma, breast cancer, non-small cell lung cancer, pediatric central nervous system tumors, and other advanced solid tumors.
Research activity is also expanding. In 2026, NCI advisers discussed a national initiative intended to accelerate cancer vaccine research, including studies of personalized RNA vaccines and “off-the-shelf” vaccine strategies in cancers with substantial unmet need.
Where different cancer vaccine approaches stand today
Vaccine approach | Intended role | Example | Current position |
Vaccine against cancer-causing virus | Prevent cancer indirectly by preventing infection | HPV vaccine | Established prevention |
Vaccine against cancer-causing virus | Prevent infection associated with cancer | Hepatitis B vaccine | Established prevention |
Cellular therapeutic vaccine | Treat existing cancer | Sipuleucel-T for certain advanced prostate cancers | Approved for a specific indication |
Personalized neoantigen vaccine | Train immunity against mutations in an individual's tumor | Experimental mRNA, peptide, and DNA vaccines | Clinical research |
Vaccine combined with immunotherapy | Strengthen or complement anticancer immune responses | Neoantigen vaccine plus checkpoint inhibitor | Clinical research |
Non-viral cancer prevention vaccine | Prevent or intercept cancer in people at elevated risk | Investigational approaches for inherited cancer risk | Early-stage research |
Could Vaccines Eventually Prevent Cancers That Are Not Caused by Viruses?
Possibly, but this is a much earlier area of research than HPV- or hepatitis B-related cancer prevention. Scientists are investigating whether people at particularly high risk of certain cancers could be vaccinated against abnormal molecular targets before invasive cancer develops.
This idea is sometimes called cancer immunoprevention or cancer interception.
Who might potentially benefit from preventive cancer vaccines?
One research strategy focuses on people whose risk can be identified before cancer develops—for example, individuals with certain inherited cancer-predisposition syndromes or precancerous conditions.
NCI has highlighted research into preventive cancer vaccines for people with Lynch syndrome, an inherited condition associated with increased risks of colorectal and several other cancers.
The NCI research program on cancer immunoprevention also identifies high-risk groups—including people with high-penetrance inherited mutations or precancerous conditions—as potential populations for future cancer-prevention strategies.
However, preventing cancer in someone who is currently healthy sets an especially high safety standard.
Researchers would need convincing evidence that a preventive vaccine meaningfully reduces cancer risk and that its potential harms are acceptably low.
For now, vaccines intended to prevent non-viral cancers should be regarded as investigational rather than established alternatives to recommended cancer screening, risk-reduction strategies, or medical surveillance.
What Are the Biggest Challenges Facing Cancer Vaccines?
The central challenge is that cancer is not one disease with one universal target. Different cancers—and even cancer cells within the same tumor—can contain different mutations and interact with the immune system differently.
A vaccine must therefore do more than generate an immune response. That immune response must reach the tumor, recognize clinically important cancer cells, remain active, and produce a meaningful benefit without causing unacceptable harm.
Other challenges include:
Selecting the most useful tumor antigens or neoantigens
Overcoming mechanisms cancers use to suppress immune responses
Dealing with differences among cells within the same tumor
Manufacturing personalized vaccines quickly enough
Determining which patients are most likely to respond
Finding the best combination with surgery, chemotherapy, radiation, or other immunotherapies
Demonstrating improved recurrence or survival outcomes in sufficiently large trials
Making successful personalized approaches practical and accessible
Cancer vaccines may therefore ultimately work best as one component of treatment rather than as a universal replacement for established therapies.
What Should Patients Know About Cancer Vaccines Today?
People should distinguish established vaccines from experimental cancer-vaccine treatments. HPV and hepatitis B vaccines have established roles in preventing infections linked to certain cancers, while therapeutic vaccines have much narrower approved uses and many personalized cancer vaccines are still being evaluated in clinical trials.
Someone with cancer should not delay or replace evidence-based treatment in order to pursue an unapproved vaccine marketed as a cancer cure. Claims about “personalized cancer vaccines” should be checked carefully to determine whether the product is an approved treatment, part of a registered clinical trial, or an unproven commercial intervention.
People interested in an experimental cancer vaccine can discuss clinical-trial eligibility with their oncology team. Whether a trial is appropriate depends on factors including cancer type, stage, previous treatments, tumor characteristics, overall health, and the study's eligibility criteria.
Conclusion
Cancer vaccines could substantially change how selected cancers are prevented or treated, but different technologies are at very different stages of development. HPV and hepatitis B vaccination already demonstrate that vaccines can prevent cancers linked to infections, while sipuleucel-T shows that therapeutic vaccination can have a role in cancer treatment. Personalized neoantigen and mRNA vaccines are producing promising early research signals, but most remain experimental and require larger trials.
For patients, promising research should not be confused with proven treatment. Cancer prevention, screening, and treatment decisions should follow established medical guidance, while experimental vaccines are best considered through qualified oncology teams and appropriately regulated clinical trials.
Frequently Asked Questions
1. Is there currently a vaccine that prevents cancer?
Yes, but existing prevention vaccines target cancer-causing infections rather than cancer itself. HPV vaccination helps prevent several HPV-related cancers, while hepatitis B vaccination helps prevent chronic HBV infection that can contribute to liver cancer. Vaccines directly preventing most non-viral cancers remain experimental.
2. Can a cancer vaccine cure someone who already has cancer?
Cancer treatment vaccines are designed to stimulate immune responses against existing cancer, but they are not universal cancer cures. Sipuleucel-T has an established role in certain advanced prostate cancers, while most newer therapeutic vaccines are experimental. Their effectiveness depends on the cancer and treatment setting.
3. What is a personalized cancer vaccine?
A personalized cancer vaccine is designed using molecular information from an individual person's tumor. Researchers can identify mutation-derived neoantigens and create a vaccine intended to teach immune cells to recognize those targets. Personalized mRNA, DNA, and peptide vaccines are currently being investigated in clinical trials.
4. Are mRNA cancer vaccines available now?
Personalized mRNA cancer vaccines are being studied in clinical trials for several cancers, but they are not routine treatment for most patients. Early studies have reported encouraging immune and recurrence findings in some settings. Larger trials are necessary to establish which approaches safely improve meaningful clinical outcomes.
5. Could cancer vaccines replace chemotherapy?
There is currently no evidence that cancer vaccines can broadly replace chemotherapy. Many experimental vaccine strategies are actually being studied alongside chemotherapy, checkpoint inhibitors, surgery, or other established treatments. Future use will depend on evidence showing which combinations provide meaningful benefits for particular cancers.
6. How can someone find a legitimate cancer vaccine clinical trial?
Start by speaking with the treating oncology team, which can assess whether an experimental vaccine is relevant to the specific cancer and treatment stage. National clinical-trial registries and major cancer research institutions also list studies. Eligibility should be confirmed by the investigators running the registered trial.
Comments